Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

3.740 +0.260 (+7.47%)
Streaming Delayed Price Updated: 11:58 AM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Curevac N.V.

< Previous 1 2 3 4 5 6 7 Next >
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday
Via Benzinga
CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q4 2023
CVAC stock results show that CureVac missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
3 Stocks to Purge ASAP Before They’re Pulled off Life Support
Here are three stocks to sell now from your portfolio before they run out of cash and collapse. Avoid throwing good money after bad. 
Via InvestorPlace
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
Earnings Preview: CureVac
Via Benzinga
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Via Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Via Benzinga
CureVac, GS Partner Release Data On Influenza Vaccine Study
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
Via Benzinga
Why Biopharmaceutical Player CureVac Shares Are Rising Today
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday. 
Via Benzinga
Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy... 
Via Benzinga
Why Is COVID-19 Vaccine Player CureVac Stock Plummeting Today?
A German court has invalidated a patent central to CureVac N.V's (NASDAQ: CVAC) lawsuit against BioNTech SE (NASDAQ: BNTX) related to seeking fair compensation for infringement of a portfolio of 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Bluebird Bio, Vertex Energy And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones index gaining around 150 points on Tuesday. Shares of bluebird bio, Inc. (NASDAQ: BLUE) shares fell sharply during Tuesday’s session after the company... 
Via Benzinga
Topics Stocks
Exposures US Equities
Acuitas Challenges CureVac in Legal Tussle Over COVID-19 Vaccine Technology
Biotech company Acuitas Therapeutics has filed a lawsuit in Virginia federal court against Germany-based CureVac SE (NASDAQ: CVAC), accusing it of failing to credit Acuitas on patents related to... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Earnings Scheduled For November 14, 2023
Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue of $18.00 million. 
Via Benzinga
Why CureVac Stock Plunged Today
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech. 
Via The Motley Fool
Topics Lawsuit
Exposures Financial Legal
Why Shares of CureVac Jumped This Week
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate. 
Via The Motley Fool
Why CureVac Stock Leaped 12% Higher Today
The war on cancer advances with the German company's latest clinical development. 
Via The Motley Fool
DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
Via Benzinga
Why CureVac Shares Are Nosediving Today
CureVac BV (NASDAQ: CVAC) shares are trading lower by 13.99% to $9.10 during Tuesday's session after the company announced a proposed public offering of common stock. What Happened? 
Via Benzinga
Why Bed Bath & Beyond Fell Almost 30%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
Via Benzinga
The 3 Best Biotech Stocks Under $1 to Buy for January
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
Via InvestorPlace
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.